Alpana Waghmare
Pediatric Infectious Diseases · Seattle, WANPI 1932368057
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,160 of the $20,475 with a category attached, or 93.6%. 4 manufacturers reported payments, led by AstraZeneca at 45.5% of the total.
Across 15 payments — averaging $1364.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Gilead$7K
- Merck$3K
- GSK$2K
Across 26 payments — averaging $27,647 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$350K
- Pfizer$234K
- Merck$136K
What the payments were for
- Consulting fees$19,16094%
- Travel & lodging$7954%
- Food & beverage$5203%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $9,315 |
| Gilead | 3 | $6,860 |
| Merck | 5 | $2,800 |
| GSK | 1 | $1,500 |
How this compares
Too few pediatric infectious diseases providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in Seattle
- Janet EnglundSeattle$248K
- Tamara PozosSeattle$8K
- Surabhi VoraSeattle$4K
- Horacio DuarteSeattle$2K
- Michael GilbertSeattle$365
- Theresa BartonSeattle$80
- Christopher WilsonSeattle$68
- Erin ChungSeattle$51
- Sara KimSeattle$43
- Soren GanttSeattle$34
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.